ClinicalTrials.gg
Not yet recruitingNCT07429162Updated Feb 24, 2026

Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection

A Phase 1 interventional study of DP-QB-MYA-002 in Mycobacterium Abscessus Infection, Bacteriophage Therapy and Pulmonary Disease, sponsored by Alberta Health services. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Alberta Health services · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.

02

Conditions studied

  • Mycobacterium Abscessus Infection
  • Bacteriophage Therapy
  • Pulmonary Disease
03

In context

Mycobacterium Infections, Nontuberculous

54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.

This study's planned enrollment of 1 is below the median of 40 across 35 interventional studies indexed under Mycobacterium Infections, Nontuberculous.

Browse Mycobacterium Infections, Nontuberculous studies →

Lead sponsor

Alberta Health services is the lead sponsor of 40 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consent to participation

Exclusion criteria

Exclusion Criteria:

  • non-consent to participation
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    Treatment

    Use of Mycobacteriophage

    Biological: DP-QB-MYA-002

Interventions

  • BiologicalDP-QB-MYA-002

    In-vitro effective Mycobacteriophage DP-QB-MYA-002 against specific strain of Mycobacterium abscessus ssp abscessuss

06

What researchers measure

Primary outcomes

  1. Time to Sputum Culture Conversion (Microbiologic Response)

    Serial AFB smear grading and serial mycobacterial sputum cultures during and post treatment

    Time frame: 1 year

Secondary outcomes

  1. Change in Volume of Sputum Production (Clinical Response)

    Patient Report

    Time frame: 1 year

  2. Change in frequency of Cough (Clinical Response)

    Patient Report

    Time frame: 1 year

  3. Change in FEV1 (Clinical Response)

    This will be assessed via spirometry at baseline and at the end of the study An increase in FEV1 indicating improvement in lung function or FEV1 decrease indicating decline in lung function.

    Time frame: 1 year

  4. Change in BMI (Clinical Response)

    Within subject change in BMI measured in kg/m\^2. Increase in BMI as a sign of improvement. Decline in BMI as sign of decline or worse outcome.

    Time frame: 1 year

  5. Radiographic Response

    Chest imaging response (CT scan) to treatment. Reduction in size, number or density of pulmonary nodules indicating improvement, whereas increased size, number or density indicating worsening.

    Time frame: 1 year

Other outcomes

  1. Adverse Effects (Clinical)

    Adverse clinical and laboratory events (number and severity) on treatment

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 24, 2026
StartEst.
Jul 2, 2026
Primary completionEst.
Jul 2, 2027
CompletionEst.
Jul 2, 2028
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07429162
Lead sponsor
Alberta Health services
Responsible party
Jenny Edwards (Doctor of Pharmacy, Alberta Health services) — Principal investigator
First posted
Feb 24, 2026
Start date
Jul 2, 2026 (estimated)
Primary completion
Jul 2, 2027 (estimated)
Completion
Jul 2, 2028 (estimated)
Last update
Feb 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion